In concert with the absence of somatic alterations affecting ABL1 and RUNX1 in 90 therapy‐naive paediatric patients with CML‐CP in our previous study,40 these current findings propose a contribution of such pathogenic gene variants to blast‐phase transformation. The gene discussed is RUNX1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.